Welcome to Medincell. Here we are committed to creating better medicines for all.
Impacting Global Health with Purposeful Innovation
Latest news & events
The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in Adults
The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in Adults
UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year‑on‑Year
UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year‑on‑Year
Degroof Petercam Initiates Medincell’s Coverage with a “Buy” Recommendation
Degroof Petercam Initiates Medincell’s Coverage with a “Buy” Recommendation
Leerink Partners Initiates Medincell’s Coverage with a “Outperform” Recommendation
Leerink Partners Initiates Medincell’s Coverage with a “Outperform” Recommendation
Improving health worldwide through new therapeutic options
Our talented team of international experts is committed to developing an innovative and diverse portfolio of breakthrough therapies.
Powered by proprietary cutting-edge long-acting injectable technology, we are redefining treatment standards in terms of efficacy and accessibility to enhance the quality of life for patients worldwide.
What is a long-acting injectable ?
In our commitment to advancing global health, we collaborate with leading pharmaceutical entities and foundations to introduce groundbreaking therapeutic solutions.
Key figures
1
FDA-approved best-in-class therapy based on our proprietary technology
2
potential first-in-class therapies in Phase 3 clinical trials
140
top-tier experts, all shareholders, steering our company's success
25
nationalities within our team, fostering a diverse and dynamic work environment
Products & R&D pipeline
At the core of our portfolio is a commitment to addressing critical medical challenges, aiming to profoundly impact not only patient lives but also society at large. Our innovative product candidates, rooted in our proprietary BEPO® long-acting injectable technology, are developed both in-house and in collaboration with leading international pharmaceutical firms and NGOs.
Products on market
Programs in clinical phase 3
mdc-TJK
In partnership with Teva Pharmaceuticals
Indication
Schizophrenia
Molecule
Olanzapine
Status
Clinical Phase 3
Technology
BEPO®
mdc-TJK is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the treatment of schizophrenia. It has the potential to be the first long-acting olanzapine with a favorable safety profile as other LAIs of olanzapine have an FDA black box warning for PDSS (Postinjection Delirium/Sedation Syndrome) that limits their use.
News related to the project
The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in Adults
The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in Adults
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults
UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) ; OLANZAPINE LAI: EU Submission Expected in Q2 2026
UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) ; OLANZAPINE LAI: EU Submission Expected in Q2 2026
Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults
Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults
UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025
UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025
New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed
New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed
Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation
Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation
UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025
UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025
UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025
UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025
Phase 3 Survey Results Demonstrate Patient and Healthcare Professional Satisfaction with Olanzapine LAI
Phase 3 Survey Results Demonstrate Patient and Healthcare Professional Satisfaction with Olanzapine LAI
mdc-CWM
In partnership with AIC
Indication
Post-op pain
Molecule
Celecoxib
Status
Clinical Phase 3
Technology
BEPO®
Injected into the intra-articular space during Total Knee Replacement surgery and potentially active for as long as three months post-surgery, mdc-CWM is a sustained-release formulation of celecoxib for the reduction of postoperative pain and inflammation. The mdc-CWM project is a collaboration with Arthritis Innovation Corporation (AIC), based in Toronto, Canada, who finance and conduct the clinical development activities.
News related to the project
Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM
Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total knee replacement
MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total knee replacement
MedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement
MedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement
MedinCell: mdc-CWM clinical phase 3 will start in 2021
MedinCell: mdc-CWM clinical phase 3 will start in 2021
MedinCell provides a portfolio update for J.P. Morgan Healthcare Conference 2020
MedinCell provides a portfolio update for J.P. Morgan Healthcare Conference 2020
MedinCell announces that mdc-CWM progresses as planned
MedinCell announces that mdc-CWM progresses as planned
Join the team
Unleash your entrepreneurial spirit within a creative and innovative team of international experts dedicated to tackling global health challenges.
Investor Presentation – April 2026
Shift to Growth
Get in touch
Please use the form for any inquiries. We’ll get back to you promptly.
